Ignite Creation Date:
2024-05-05 @ 4:53 PM
Last Modification Date:
2024-10-26 @ 9:25 AM
Study NCT ID:
NCT00336765
Status:
COMPLETED
Last Update Posted:
2022-05-13
First Post:
2006-06-12
Brief Title:
Study of XL647 Administered Orally Daily to Patients With Solid Tumors
Sponsor:
Kadmon Corporation LLC
Organization:
Kadmon Corporation LLC
Study Overview
Official Title:
A Phase 1 Dose-Escalation Study of the Safety and Pharmacokinetics of XL647 Administered Orally Daily to Subjects With Solid Tumors
Status:
COMPLETED
Status Verified Date:
2022-05
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to assess the safety and tolerability of the multiple receptor tyrosine kinase RTK inhibitor including EGFR VEGFR2 ErbB2 and EphB4 XL647 when given orally daily to adults with advanced solid tumors
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None